Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 4, Issue 5, 2004, Pages 537-547

  Hoch, Jeffrey S ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Cost utility; Cost effectiveness; Multiple sclerosis; Rationing

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; RECOMBINANT ERYTHROPOIETIN;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; MULTIPLE SCLEROSIS; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 5444237090     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.4.5.537     Document Type: Review

References (91)

1. Clegg A, Bryant J, Milne R. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technol. Assess. 4(9), 1-101 (2000).
2. Markovic-Plese S, Pinilla C, Martin R. The initiation of the autoimmune response in multiple sclerosis. Clin. Neurol. Neurosurg. 106(3), 218-222 (2004).
3. National Institute for Clinical Excellence. Multiple sclerosis - Management of multiple sclerosis in primary and secondary care. NICE Technology Appraisal Guidance No. 8. National Institute for Clinical Excellence, London, UK (2003).
4. Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol. Assess. 6(10), 1-73 (2002).
5. Compston A, Coles A. Multiple sclerosis. Lancet 359 1221-1231 (2002).
6. Victor M, Ropper AH. Multiple sclerosis and allied demyelinative diseases. In: Adams and Victor's Principles of Neurology. Seventh Edition. McGraw-Hill, NY, USA, 954-982 (2001).
7. Chilcott J, McCabe C, Tappenden P et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Br. Med. J. 326(7388), 522-525 (2003).
8. Vukusic S, Confavreux C. The natural history of multiple sclerosis. In: Handbook of Multiple Sclerosis. Third Edition. Cook SD (Ed.). Marcel Dekker, MY, USA, 433-447 (2001).
9. Paty DW, Noseworthy J, Ebers GC. Diagnosis of multiple sclerosis. In: Multiple Sclerosis. Paty DW, Ebers GC (Eds). FA Davis, PA, USA, 48-134 (1997).
10. Henriksson F, Fredrikson S, Masterman T, Jonsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur. J. Neurol. 8(1), 27-35 (2001).
11. Flachenecker P, Rieckmann P. Early intervention in multiple sclerosis: better outcomes for patients and society? Drugs 63(15), 1525-1533 (2003).
12. Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis - a geographically based study. Brain 112, 133-146 (1989).
13. O'Connor P, Arnold DL, Bouchard JP et al. Key issues in the diagnosis and treatment of multiple sclerosis: an overview. Neurology 59(6 Suppl. 3), S1-S33 (2002).
14. Bryant J, Clegg A, Milne R. Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: is there good quality evidence on effectiveness and cost? J. Neurol. Neurosurg. Psych. 70(5), 574-579 (2001).
15. Poser CM, Brinar VV. The nature of multiple sclerosis. Clin. Neurol. Neurosurg. 106(3), 159-171 (2004).
16. Filippini G, Munari L, Incorvaia B et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361(9357), 545-552 (2003).
17. Keegan BM, Noseworthy JH. Multiple sclerosis. Ann. Rev. Med. 53, 285-302 (2002).
18. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Medical progress: multiple sclerosis. N. Engl. J. Med. 343(13), 938-952 (2000).
19. Duquette P, Girard M, Despault L et al. The IFNB Multiple Sclerosis Study Group. IFN-α-1b is effective in relapsing-remitting multiple-sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4), 655-661 (1993).
20. Duquette P, Despault L, Knobler RL et al. IFN-α-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45(7), 1277-1285 (1995).
21. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-1-α for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39(3), 285-294 (1996). Erratum in: Ann. Neurol. 40(3), 480 (1996).
22. Ebers GC, Rice G, Lesaux J et al. Randomised double-blind placebo-controlled study of interferon-β-1a in relapsing/remitting multiple sclerosis. Lancet 352(9139), 1498-1504 (1998). Erratum in: Lancet 353(9153), 678 (1999).
23. Kappos L, Polman C, Pozzilli C et al. Placebo-controlled multicentre randomised trial of interferon-β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352(9139), 1491-1497 (1998).
24. Richards RG. Interferon-β in multiple sclerosis. Br. Med. J. 313(7066), 1159 (1996).
25. Tolley KH, Whynes DK. Interferon-β in multiple sclerosis - can we control its costs? PharmacoEconomics 11(3), 210-215 (1997).
26. Dowie J. Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant. Health Econ. 13(5), 453-459 (2004).
27. Drummond MF, O'Brien BJ, Torrance GW, Stoddart GL. Methods for the economic evaluation of health care programmes. Second Edition. Oxford University Press, Oxford, UK (1997).
28. Goodacre S, McCabe C. Being economical with the truth: how to make your idea appear cost effective. Emerg. Med. J. 19(4), 301-304 (2002).
29. Drummond MF. Method without madness. Expert Rev. Pharmacoeconomics Outcomes Res. 2(4), 305-307 (2002).
30. Sturm R, Wells KB. How can care for depression become more cost-effective? JAMA 273(1), 51-58 (1995).
31. Gold MR, Stevenson D, Fryback DG. HALYS and QALYS and DALYS, oh my: similarities and differences in summary measures of population health. Ann. Rev. Pub. Health 23, 115-134 (2002).
32. Krabbe PFM, Essink-Bot ML, Bonsel GJ. The comparability and reliability of five health-state valuation methods. Soc. Sci. Med. 45(11), 1641-1652 (1997).
33. Arnesen T, Trommald M. Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. J. Health Serv. Res. Policy. 9(1), 43-50 (2004).
34. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Patient and community preferences for treatments and health states in multiple sclerosis. Mult. Scler. 9(3), 311-319 (2003).
35. Shumway M. Preference weights for cost-outcome analyses of schizophrenia treatments: comparison of four stakeholder groups. Sch. Bull. 29(2), 257-266 (2003).
36. Heller JG. Will public health survive QALYs? Can. J. Clin. Pharmacol. 9(1), 5-6 (2002).
37. Lepen C, Coyle P, Vollner T, Blumhardt L, Lilliu H, Beresniak A. Long-term cost effectiveness of interferon-β-1a in the treatment of relapsing-remitting multiple sclerosis. An econometric model. Clin. Drug Invest. 23(9), 571-581 (2003).
38. Bose U, Ladkani D, Burrell A, Sharief M. Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. J. Med. Econ. 4, 207-219 (2001).
39. Parkin D, McNamee P, Jacoby A, Miller P, Thomas S, Bates D. A cost-utility analysis of interferon-β for multiple sclerosis. Health Technol. Assess. 2(4), 3-54 (1998).
40. McNamee P, Parkin D. Cost-effectiveness of interferon β for multiple sclerosis: the implications of new information on clinical effectiveness. Health Technol. Assess. 2(4), 59-66 (1999).
41. Phillips CJ, Gilmour L, Gale R, Palmer M. A cost utility model of interferon β-interferon in the treatment of relapsing-remitting multiple sclerosis. J. Med. Econ. 4, 35-50 (2001).
42. Kendrick M, Johnson KI. Long term treatment of multiple sclerosis with interferon-β may be cost effective. PharmacoEconomics 18(1), 45-53 (2000).
43. Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon β in multiple sclerosis: a Markov process analysis. Value Health 5(1), 44-54 (2002).
44. Brown MG, Murray TJ, Sketris IS et al. Cost-effectiveness of interferon β-1b in slowing multiple sclerosis disability progression: first estimation. Int. J. Technol. Assess. Health Care 16(3), 751-767 (2000).
45. Nicholson T, Milne R. Copolymer 1 in relapsing-remitting multiple sclerosis. Southampton. Wessex Institute for Health Research and Development, Development and Evaluation Committee Report No. 63 (1996).
46. Nicholson T, Milne R. β interferons (1a and 1b) in relapsing-remitting and secondary multiple sclerosis. Wessex Institute for Health Research and Development, Development and Evaluation Committee, Southampton, UK. Report No. 98 (1999).
47. Otten N. Comparison of drug treatments for multiple sclerosis. Canadian Coordinating Office for Health Technology Assessment, Ottawa, Canada (1998).
48. Forbes RB, Lees A, Waugh N, Swingler RJ. Population based cost utility study of interferon β-1b in secondary progressive multiple sclerosis. Br. Med. J. 319(7224), 1529-1533 (1999).
49. Touchette DR, Durgin TL, Wanke LA, Goodkin DE. A cost-utility analysis of mitoxantrone hydrochloride and interferon β-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin. Ther. 25(2), 611-634 (2003).
50. Rubio-Terres C, Aristegui R, I, Medina RF, Izquierdo AG. Cost-utility analysis of multiple sclerosis treatment with glatiramer acetate or interferon β in Spain. Farm. Hosp. 27(3), 159-165 (2003).
51. Kobelt G, Jönsson L, Henriksson F, Fredrikson S, Jonsson B. Cost-utility analysis of interferon-β-1b in secondary progressive multiple sclerosis. Int. J. Technol. Assess. Health Care 16(3), 768-780 (2000).
52. Kobelt G, Jönsson L, Miltenburger C, Jonsson B. Cost-utility analysis of interferon-β-1b in secondary progressive multiple sclerosis using natural history disease data. Int. J. Technol. Assess. Health Care. 18(1), 127-138 (2002).
53. Kobelt G, Jönsson L, Fredrikson S. Cost-utility of interferon-β-1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. Eur. J. Health Econ. 4, 50-59 (2003).
54. Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon b: an appraisal of cost-effectiveness and quality of life. J. Neurol. Neurosurg. Psychiatry 68(2), 144-149 (2000).
55. Clegg A, Bryant J. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness. Expert Opinion Pharmacotherapy 2(4), 623-639 (2001).
56. Pryse-Phillips W. Newer long-term treatments for multiple sclerosis. Clin. Neurol. Neurosurg. 104(3), 265-271 (2002).
57. Newhouse JP. US and UK health economics: two disciplines separated by a common language? Health Econ. 7, S79-S92 (1998).
58. Flachenecker P, Rieckmann P. Health outcomes in multiple sclerosis. Curr. Opin. Neurol. 17(3), 257-261 (2004).
59. Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs 18(9), 561-574 (2004).
60. Bronnum-Hansen H, Koch-Henriksen N, Hyllested K. Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey. Neurology 44(10), 1901-1907 (1994).
61. Blumhardt LD, Wood C. The economics of multiple sclerosis: a cost of illness study. Br. J. Med. Economics. 10, 99-118 (1996).
62. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis. Part I: cost of illness. Can. J. Neurol. Sci. 25(1), 23-30 (1998).
63. Henriksson F, Jonsson B. The economic cost of multiple sclerosis in Sweden in 1994. PharmacoEconomics 13(5), 597-606 (1998).
64. Holmes J, Madgwick T, Bates D. The cost of multiple sclerosis. Br. J. Med. Economics 8, 181-193 (1995).
65. Murphy N, Confavreux C, Haas J et al. Economic evaluation of multiple sclerosis in the UK, Germany and France. PharmacoEconomics 13(5), 607-622 (1998).
66. O'Brien BJ. Multiple Sclerosis. Office of Health Economics, London, UK (1987).
67. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 11(5), 415-430 (2002).
68. Naylor CD, Williams JI, Basinski A, Goel V. Technology assessment and cost-effectiveness analysis: misguided guidelines? CMAJ 148(6), 921-924 (1993).
69. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization - tentative guidelines for using clinical and economic evaluations. CMAJ 146(4), 473-481 (1992).
70. Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? CMAJ 166(1), 44-47 (2002).
71. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med. Decis. Making 20(3), 332-342 (2000).
72. Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ. 12(12), 1049-1060 (2003).
73. George B, Harris A, Mitchell A. Cost effectiveness analysis and the consistency of decision making - evidence from pharmaceutical reimbursement in Australia (1991 to 1996). PharmacoEconomics 19(11), 1103-1109 (2001).
74. Towse A. What is NICE's threshold? An external view. In: Cost Effectiveness Thresholds: Economic and Ethical Issues. Devlin N, Towse A (Eds). King's Fund/Office for Health Economics, London, UK (2002).
75. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 13(5), 437-452 (2004).
76. Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. CMAJ 148(6), 913-917 (1993).
77. Donaldson C, Currie G, Mitton C. Cost effectiveness analysis in health care: contraindications. Br. Med. J. 325(7369), 891-894 (2002).
78. Gafni A, Birch S. Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures? CMAJ 168(7), 849-851 (2003).
79. Devlin N, Appleby J, Parkin D. Patients' views of explicit rationing: what are the implications for health service decision-making?. J. Health Serv. Res. Policy 8(3), 183-186 (2003).
80. Lie RK. Research ethics and evidence based medicine. J. Med. Ethics 30, 122-125 (2004).
81. Banta HD, Thacker SB. The case for reassessment of health care technology: once is not enough. JAMA 264(2), 235-240 (1990).
82. Leese B, Hutton J, Maynard A. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in five European countries. PharmacoEconomics 1(5), 346-356 (1992).
83. Remak E., Hutton J, Jones MM, Zagari M. Changes in cost-effectiveness over time: the case of epoetin α for renal replacement therapy patients in the UK. Eur. J. Health Econ. 4, 115-121 (2003).
84. Sudlow CLM, Counsell CE. Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. Br. Mrd. J. 326(7385), 388-392 (2003).
85. Zaric G, Hoch JS. Pharmaceutical risk sharing based on net monetary benefits. (2004) (In Press).
86. Herndon RM, Jacobs L. Interferons should be used to treat most patients with MS. Arch. Neurol. 55(12), 1581-1583 (1998).
87. Petrou S, Wolstenholme J. A review of alternative approaches to healthcare resource allocation. PharmacoEconomics 18(1), 33-43 (2000).
88. Anell A. Priority setting for pharmaceuticals: the use of health economic evidence by reimbursement and clinical guidance committees. Eur. J. Health Econ. 5, 28-35 (2004).
89. Laupacis A, Paterson JM, Mamdani M, Rostom A, Anderson GM. Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach. CMAJ 169(11), 1167-1170 (2003).
90. Pittock SJ, Mayr WT, McClelland RL et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 62(4), 601-606 (2004).
91. Meyer CM, Phipps R, Cooper D, Wright A. Pharmacy benefit forecast for a new interferon-β-1a for the treatment of multiple sclerosis: development of a first-line decision tool for pharmacy-budget planning using administrative claims data. J. Manag. Care Pharm. 9(2), 168-174 (2003).